Millennium Pharmaceuticals Inc's Form 4 filing
Day One Biopharmaceuticals, Inc. (DAWN) · filed Dec 7, 2021
- Accession no.
- 0001395064-21-000246
- Filed
- Dec 7, 2021, 6:01 AM ET
- Trade date
- Dec 3-6, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $1.99M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Millennium Pharmaceuticals IncCIK 0001002637 | 10% Owner |
| Takeda Pharmaceutical Co LtdCIK 0001395064 | 10% Owner |
| Takeda Pharmaceuticals U.S.A., Inc.CIK 0001716229 | 10% Owner |
| Takeda Ventures, Inc.CIK 0001771657 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $18.10 to $18.78. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.
Referenced by the price of 1 transaction in Table I.
- F5
Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $18.00 to $18.27. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.
Referenced by the price of 1 transaction in Table I.